AIM： To evaluate the frequency of neural cell adhesion molecule （NCAM）-180 expression in fresh tumor tissue samples and to discuss the prognostic value of NCAM-180 in routine clinical practice.METHODS： Twenty-six ...AIM： To evaluate the frequency of neural cell adhesion molecule （NCAM）-180 expression in fresh tumor tissue samples and to discuss the prognostic value of NCAM-180 in routine clinical practice.METHODS： Twenty-six patients （16 men, 10 women） with colorectal cancer were included in the study. Fresh tumor tissue samples and macroscopically healthy proximal margins of each specimen were subjected to flow-cytometric analysis for NCAM-180 expression.RESULTS： Flow-cytometric analysis determined NCAM-180 expression in whole tissue samples of macroscopically healthy colorectal tissues. However, NCAM-180 expression was positive in only one case （3.84%） with well-differentiated Stage Ⅱ disease who experienced no active disease at 30 months follow-up. CONCLUSION： As a consequence of the limited number of cases in our series, it might not be possible to make a generalisation, nevertheless the routine use of NCAM-180 expression as a prognostic marker for colorectal carcinoma seems to be unfeasible and not cost-effective in clinical practice due to its very low incidence.展开更多
文摘AIM： To evaluate the frequency of neural cell adhesion molecule （NCAM）-180 expression in fresh tumor tissue samples and to discuss the prognostic value of NCAM-180 in routine clinical practice.METHODS： Twenty-six patients （16 men, 10 women） with colorectal cancer were included in the study. Fresh tumor tissue samples and macroscopically healthy proximal margins of each specimen were subjected to flow-cytometric analysis for NCAM-180 expression.RESULTS： Flow-cytometric analysis determined NCAM-180 expression in whole tissue samples of macroscopically healthy colorectal tissues. However, NCAM-180 expression was positive in only one case （3.84%） with well-differentiated Stage Ⅱ disease who experienced no active disease at 30 months follow-up. CONCLUSION： As a consequence of the limited number of cases in our series, it might not be possible to make a generalisation, nevertheless the routine use of NCAM-180 expression as a prognostic marker for colorectal carcinoma seems to be unfeasible and not cost-effective in clinical practice due to its very low incidence.
